Business
Nuvalent to Present New Preclinical and Clinical Data for Zidesamtinib, an Investigational ROS1-Selective Inhibitor, at AACR Annual Meeting 2026
CAMBRIDGE, Mass., March 17, 2026 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely
About this update from Nuvalent, Inc.
[{"type":"text","content":"CAMBRIDGE, Mass., March 17, 2026 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the presentation of new data for zidesamtinib, an investigational ROS1-selective inhibitor, during two poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026, being held April 17-22 in San Diego. The posters will highlight clinical data from a subset of TKI pre-treated patients with ROS1-positive NSCLC treated in the ARROS-1 Phase 1/2 clinical trial and preclinical data further characterizing zidesamtinib's brain penetrance and intracranial activity.\n \n \n \n \n \n \n \nDetails of the poster presentations are as follows:Title: Zidesamtinib in Patients with ROS1+ NSCLC Previously Treated with Repotrectinib or TaletrectinibPresenting Author: Geoffrey Liu, M.Sc., M.D.1Abstract Number: CT248Session Title: Phase II Clinical TrialsSession Date and Time: Tuesday, April 21, 2026, 2:00-5:00 p.m. PTLocation: Poster Section 50Poster Board Number: 13Title: Zidesamtinib Has Differentiated Preclinical Brain Penetrance and Intracranial Activity Compared to Other ROS1 InhibitorsPresenting Author: Anupong Tangpeerachaikul, Ph.D.2Abstract Number: LB366Session Title: Late-Breaking Research: Experimental and Molecular Therapeutics 3Session Date and Time: Tuesday, April 21, 2026, 2:00-5:00 p.m. PTLocation: Poster Section 53Poster Board Number: 231 Princess Margaret Hospital, Toronto, Ontario, Canada; 2 Nuvalent, Inc., Cambridge, MA, USAAbout ZidesamtinibZidesamtinib is an investigational, brain-penetrant, ROS1-selective inhibitor created with the aim to overcome limitations observed with currently available ROS1 inhibitors. Zidesamtinib is designed to remain active in tumors that have developed resistance to currently available ROS1 inhibitors, including tumors with treatment-emergent ROS1 mutations such as G2032R. In addition, zidesamtinib is designed for central nervous system (CNS) penetrance to improve treatment options for patients with brain metastases, and to avoid inhibition of the structurally related tropomyosin receptor kinase (TRK) family. Together, these characteristics have the potential to avoid TRK-related CNS adverse events seen with dual TRK/ROS1 inhibitors ...